高级检索
当前位置: 首页 > 详情页

Molecular Subtyping of Hepatocellular Carcinoma via Lysosome-Related Genes for Prognosis and Therapy Prediction

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Gastroenterology, Qidong People's Hospital, Nantong, People's Republic of China. [2]Department of Breast Surgery, Panjin Central Hospital, Panjin, People's Republic of China. [3]Department of General Practice, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China. [4]Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, People's Republic of China. [5]Department of General Surgery, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China. [6]Liaoning Provincial Key Laboratory of Precision Medicine for Malignant Tumors, Shenyang, People's Republic of China. [7]Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
出处:
ISSN:

关键词: hepatocellular carcinoma lysosomes tumor immune prognosis tumor microenvironment molecular subtypes

摘要:
Lysosomes play an important role in the pathological processes of cancer development. However, its effects on the prognosis and tumor microenvironment of hepatocellular carcinoma (HCC) remain unclear. Therefore, we aim to explore the novel molecular subtypes of HCC via lysosome-related genes (LRGs) for prognosis and therapy prediction in this study.Using the data of TCGA, differential expression and survival analyses were performed. Consequently, 109 key LRGs were obtained and 374 HCC samples were clustered into two groups: C1 and C2. A three-gene prognostic prediction nomogram was constructed using WCGNA and Cox regression analyses. Furthermore, pathway enrichment conditions, immune infiltration, immune checkpoint expression, and drug sensitivity were analyzed for the two subtypes. RT-qPCR was also used to validate the expression of the selected key LRGs.Key LRGs were highly expressed in the C1 subtype, and their prognosis was worse. The degree of immune cell infiltration and pathway enrichment results were also significantly different between the two subtypes. Furthermore, the three-gene prognostic prediction nomogram including LAPTM4B, PRKCD and LPCAT1, had a relatively high prognostic prediction ability. Meanwhile, the expression of immune checkpoints, human leukocyte antigen, and TIDE score were higher in the C1 subtype, suggesting that immune evasion was more likely to occur in this subtype. Drug sensitivity analysis showed that several drugs were more sensitive to C1 subtypes and might serve as drug candidates for these patients.We identified two novel molecular subtypes of HCC based on LRGs, and found that the LRGs related subtypes demonstrated significant efficacy in predicting the prognosis and therapeutic outcomes for patients with HCC. Moreover, a novel prognostic prediction nomogram was also developed, which possessed excellent prognostic prediction capabilities. We hope the novel LRG-related subtypes and nomogram of HCC would provide new insights and guidelines for clinical practice in the future.© 2025 Yao et al.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2024]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Department of Gastroenterology, Qidong People's Hospital, Nantong, People's Republic of China.
共同第一作者:
通讯作者:
通讯机构: [5]Department of General Surgery, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China. [6]Liaoning Provincial Key Laboratory of Precision Medicine for Malignant Tumors, Shenyang, People's Republic of China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28514 今日访问量:5 总访问量:1589 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)